Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma
Yun Yen, Samuel So, Michal Rose, M Wasif Saif, Edward Chu, Shwu-Huey Liu, Angeline Foo, Zaoli Jiang, Tahmun Su, Yung-Chi Cheng, Yun Yen, Samuel So, Michal Rose, M Wasif Saif, Edward Chu, Shwu-Huey Liu, Angeline Foo, Zaoli Jiang, Tahmun Su, Yung-Chi Cheng
Abstract
PHY906 is a Chinese medicine formula with claims for the treatment of severe gastrointestinal distress. PHY906 enhanced the therapeutic index of various chemotherapeutic agents in human hepatocellular carcinoma xenografts. Accordingly, here a phase I/II clinical study was conducted with the combination of capecitabine in patients with advanced, unresectable hepatocellular carcinoma. More than 60% of patients had either stable disease or better after two treatment cycles. Median overall survival was 9.2 months. Asian patients had a higher median overall survival (16.5 months) than non-Asian patients (6.2 months, p=0.03). Patients' quality of life did not deteriorate significantly during treatment. This finding supported further investigation of PHY906 as an adjuvant therapy of capecitabine in a larger hepatocellular cancer population.
Source: PubMed